Skip to main content

Advertisement

Springer Nature Link
Log in

Management of Refractory Acute Myeloid Leukemia: Re-induction Therapy or Straight to Transplantation?

  • Acute Myelogenous Leukemia (EJ Feldman, Section Editor)
  • Published:
Current Hematologic Malignancy Reports Aims and scope Submit manuscript

Abstract

Patients with primary resistant and relapsed acute myeloid leukemia (AML) are rarely cured without undergoing allogeneic stem cell transplantation. What is currently debated is whether a trial of re-induction chemotherapy prior to transplantation is beneficial. Data from multiple retrospective analyses have shown that pretreatment variables are useful in predicting response to salvage chemotherapy. For patients unlikely to respond, re-induction attempts may be detrimental, leading to added organ toxicity and possible increased tumor resistance. Allogeneic transplantation in the setting of active disease is the alternative strategy. Multiple studies have demonstrated the feasibility of this approach, but cure rates have been low with the use of traditional transplant approaches. Newer strategies employing allogeneic transplantation earlier in patients with relapsed or refractory AML, as well as the incorporation of novel and effective antileukemic agents into the transplant conditioning regimen, may lead to better outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. Burnett A, Wetzler M, Löwenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol. 2011;29(5):487–94.

    Article  PubMed  Google Scholar 

  2. Sierra J, Storer B, Hansen JA, Bjerke JW, et al. Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA- matching, and marrow cell dose. Blood. 1997;90(11):4226–35.

    Google Scholar 

  3. Estey E, Thall P, David C. Design and analysis of trials of salvage therapy in acute myelogenous leukemia. Cancer Chemother Pharmacol. 1997;40(Suppl):S9–12.

    Article  PubMed  Google Scholar 

  4. Breems DA, Van Putten WL, Huijgens PC, et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol. 2005;23(9):1969–78.

    Article  PubMed  Google Scholar 

  5. •• Chevallier P, Labopin M, Turlure P, et al. A new Leukemia Prognostic Scoring System for refractory/relapsed adult acute myelogeneous leukaemia patients: a GOELAMS study. Leukemia 2011;25(6):939–44. This is a recent review of variables predicting response to salvage therapy in AML.

    Article  PubMed  CAS  Google Scholar 

  6. Ravandi F, Cortes J, Faderl S, et al. Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy. Blood. 2010;116(26):5818–23.

    Article  PubMed  CAS  Google Scholar 

  7. Giles F, O’Brien S, Cortes J, et al. Outcome of patients with acute myelogenous leukemia after second salvage therapy. Cancer. 2005;104(3):547–54.

    Article  PubMed  Google Scholar 

  8. Biggs JC, Horowitz MM, Gale RP, et al. Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy. Blood. 1992;80(4):1090–3.

    PubMed  CAS  Google Scholar 

  9. Brown RA, Wolff SN, Fay JW, et al. High-dose etoposide, cyclophosphamide and total body irradiation with allogeneic bone marrow transplantation for resistant acute myeloid leukemia: a study by the North American Marrow Transplant Group. Leuk Lymphoma. 1996;22(3–4):271–7.

    Article  PubMed  CAS  Google Scholar 

  10. Oyekunle AA, Kröger N, Zabelina T, et al. Allogeneic stem-cell transplantation in patients with refractory acute leukemia: a long-term follow-up. Bone Marrow Transplant. 2006;37(1):45–50.

    PubMed  CAS  Google Scholar 

  11. Michallet M, Thomas X, Vernant JP, et al. Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Société Française de Greffe de Moelle (SFGM). Bone Marrow Transplant. 2000;26(11):1157–63.

    Article  PubMed  CAS  Google Scholar 

  12. •• Duval M, Klein JP, He W, et al. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol. 2010;29(23):3730–8. This is the largest series of allogeneic transplants for refractory AML.

    Article  Google Scholar 

  13. Schmid C, Schleuning M, Schwerdtfeger R, et al. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood. 2006;108(3):1092–9.

    Article  PubMed  CAS  Google Scholar 

  14. Feldman EJ, Lancet JE, Kolitz JE, et al. First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. J Clin Oncol. 2011;29(8):979–85.

    Article  PubMed  CAS  Google Scholar 

  15. Gergis U, Ritchie E, Roboz GJ, et al. A novel sequential treatment utilizing CPX-351 as salvage chemotherapy followed by a reduced intensity conditioning allogeneic stem-cell transplantation for patients with refractory leukemia. Biol Blood Marrow Transplant. 2011;17(2):S305–6. Supplement.

    Article  Google Scholar 

  16. Scatena CD, Kumer JL, Arbitrario JP, et al. Voreloxin, a first-in-class anticancer quinolone derivative, acts synergistically with cytarabine in vitro and induces bone marrow aplasia in vivo. Cancer Chemother Pharmacol. 2010;66(5):881–8.

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Weill Cornell Medical College and New York-Presbyterian Hospital, 520 E. 70th Street, Starr Pavilion, 3rd Floor, New York, NY, 10021, USA

    E. J. Feldman & Usama Gergis

Authors
  1. E. J. Feldman
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. Usama Gergis
    View author publications

    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence to E. J. Feldman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Feldman, E.J., Gergis, U. Management of Refractory Acute Myeloid Leukemia: Re-induction Therapy or Straight to Transplantation?. Curr Hematol Malig Rep 7, 74–77 (2012). https://doi.org/10.1007/s11899-011-0101-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11899-011-0101-2

Keywords